BIOGEN for BIOGEN
What was lobbied
4 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Build Back Better Act, including provisions related to tax CMS/NCD draft decision on monoclonal antibodies
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR | — |
| JONATHAN CAUSEY | — |
| AMY DEMSKE | — |
| JOHN RAYMOND GIBSON | — |
| DANIEL HARDER New | Committee on Ways and Means, Clerk, 2/2014-12/2014 Rep. Michael Bishop, LA and LD, 1/2015-4/2018 |
| ALI LAKHANI New | — |
Medicare/Medicaid MMM
Discussions regarding coverage, coding, and reimbursement issues
| Lobbyist | Covered position, as disclosed |
|---|---|
| AMY ABADIR | — |
| AMY DEMSKE | — |
| TYLER HANSON | — |
Pharmacy PHA
H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle
| Lobbyist | Covered position, as disclosed |
|---|---|
| JONATHAN CAUSEY | — |
| DANIEL HARDER New | Committee on Ways and Means, Clerk, 2/2014-12/2014 Rep. Michael Bishop, LA and LD, 1/2015-4/2018 |
Taxation/Internal Revenue Code TAX
Issues related to tax reform and tax policy Tax Cuts and Jobs Act of 2017 (P.L.115-97)
| Lobbyist | Covered position, as disclosed |
|---|---|
| DANIEL HARDER New | Committee on Ways and Means, Clerk, 2/2014-12/2014 Rep. Michael Bishop, LA and LD, 1/2015-4/2018 |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.